

Changes in preterm birth and stillbirth during COVID-19 lockdowns in 26 countries

Received: 29 April 2022

Accepted: 6 January 2023

Published online: 27 February 2023

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Preterm birth (PTB) is the leading cause of infant mortality worldwide. Changes in PTB rates, ranging from -90% to $+30\%$, were reported in many countries following early COVID-19 pandemic response measures ('lockdowns'). It is unclear whether this variation reflects real differences in lockdown impacts, or perhaps differences in stillbirth rates and/or study designs. Here we present interrupted time series and meta-analyses using harmonized data from 52 million births in 26 countries, 18 of which had representative population-based data, with overall PTB rates ranging from 6% to 12% and stillbirth ranging from 2.5 to 10.5 per 1,000 births. We show small reductions in PTB in the first (odds ratio 0.96, 95% confidence interval 0.95–0.98, P value <0.0001), second (0.96, 0.92–0.99, 0.03) and third (0.97, 0.94–1.00, 0.09) months of lockdown, but not in the fourth month of lockdown (0.99, 0.96–1.01, 0.34), although there were some between-country differences after the first month. For high-income countries in this study, we did not observe an association between lockdown and stillbirths in the second (1.00, 0.88–1.14, 0.98), third (0.99, 0.88–1.12, 0.89) and fourth (1.01, 0.87–1.18, 0.86) months of lockdown, although we have imprecise estimates due to stillbirths being a relatively rare event. We did, however, find evidence of increased risk of stillbirth in the first month of lockdown in high-income countries (1.14, 1.02–1.29, 0.02) and, in Brazil, we found evidence for an association between lockdown and stillbirth in the second (1.09, 1.03–1.15, 0.002), third (1.10, 1.03–1.17, 0.003) and fourth (1.12, 1.05–1.19, <0.001) months of lockdown. With an estimated 14.8 million PTB annually worldwide, the modest reductions observed during early pandemic lockdowns translate into large numbers of PTB averted globally and warrant further research into causal pathways.

Approximately 10% of babies are born preterm (that is, before 37 completed weeks gestation), corresponding to nearly 15 million preterm births annually¹. Preterm birth and related complications are the leading cause of infant mortality, and those who survive face an increased risk of morbidity and mortality across the life course². While most preterm births are spontaneous, some are planned to reduce the risk of adverse outcomes including stillbirth, which account for two million in utero deaths globally each year^{3,4}. A decline in preterm birth rates can therefore be an indicator that high-risk women and their babies

are not receiving timely, quality care, potentially leading to increases in stillbirths.

In the first few months following the introduction of pandemic-related restrictions (henceforth referred to as 'lockdowns') in response to the first wave of coronavirus disease 2019 (COVID-19), there were markedly varying reports of changes in preterm birth and stillbirth rates across countries. Substantial reductions in preterm birth were reported from a number of high-income countries (HICs), including Australia (29–36%) (refs. ^{5,6}), Israel (40%) (ref. ⁷) and some

✉ e-mail: david.burgner@mcri.edu.au; sarah.stock@ed.ac.uk; meghan.azad@umanitoba.ca

European countries (16–91%) (refs. ^{8–13}). Conversely, data from Nepal, Uruguay and California showed increases of 11–30% in preterm birth rates^{14–16}, whereas national data from Canada, Spain, Sweden and the United States indicated small or no changes^{17–22}. In parallel, studies from low- and middle-income countries (LMICs; Nepal and Nigeria) and HICs (the UK and Italy) reported increases in stillbirth rates of 2–22% (refs. ^{12,14,23,24}), but few studies analysed preterm birth and stillbirth simultaneously.

There have been several systematic reviews and meta-analyses examining the impact of pandemic restrictions on perinatal outcomes. These studies have generally found insufficient evidence to suggest an overall change in global preterm birth and stillbirth rates, but they have reported changes in certain subgroups^{25–27}. For example, when restricting to studies from HIC settings, Chmielewska et al. found a decrease in preterm birth rates (crude odds ratio (OR) 0.91, 95% confidence interval (CI) 0.84–0.99; 795,105 pregnancies from 12 studies) and an increase in stillbirth rates (OR 1.28, 95% CI 1.07–1.54; 367,288 pregnancies from 12 studies)²⁷. However, comparison across studies was hampered by methodological differences. Notably, only one study in the review accounted for pre-pandemic trends in preterm births in their analysis^{10,28}. Additionally, most studies used facility-based data, which are difficult to interpret because changes in perinatal outcome rates at individual health facilities could reflect lockdown-induced changes in healthcare delivery (for example, diversion of high-risk births from one facility to another) rather than true population-level changes in perinatal outcomes. Indeed, a living systematic review and meta-analysis demonstrated important differences in the estimated impact of pandemic restrictions on preterm birth, depending on whether the study used single-centre (10% relative reduction: adjusted OR 0.90, 95% CI 0.86–0.94; 183,422 pregnancies from 20 studies) or regional/national-level data (no change: adjusted OR 0.99, 95% CI 0.94–1.03; 1,385,403 pregnancies from eight studies)²⁶.

While methodological challenges have hindered robust conclusions on whether lockdowns led to reductions in preterm births, there were undoubtedly unprecedented health, social and economic impacts that occurred as part of lockdowns that could potentially lead to reductions in preterm birth rates²⁹. The most well-established cause of spontaneous preterm birth is infection³⁰, and it is plausible that an immediate and substantial reduction in circulating infections during lockdown, due to reductions in social interaction and increased hygiene measures^{31,32}, could directly influence preterm birth rates. Additionally, observational studies have shown an increased risk of poor pregnancy outcomes at times of high air pollution, particularly in association with exposure in the third trimester^{33,34}; thus, reductions in air pollution linked with lockdown could potentially have an immediate impact on preterm birth^{35,36}. It is, however, also plausible that any reduction in preterm birth rates might signal that high-risk women were not receiving timely and quality maternity care³⁷, and the reduction in preterm births may have been offset by an increase in stillbirths.

In this Article, given the uncertainties in the available evidence on the impact of COVID-19 pandemic lockdowns on perinatal outcomes, particularly where studies have not used population-based data, we aimed to conduct a rigorous, standardized analysis using high-quality data from across the world through the International Perinatal Outcomes in the Pandemic (iPOP) study. Specifically, we explored whether lockdowns in response to the first wave of the COVID-19 pandemic were associated with a change in preterm birth rates using interrupted time series (ITS) analysis, and whether any associations identified varied by country income level or by type or timing of preterm birth, or could be explained by changes in stillbirth rates. Detailed time-series data enabled us to use pre-lockdown trends in preterm birth and stillbirth rates to forecast the expected trend in these outcomes had lockdown not occurred, and compare these forecasted rates with the observed rates for each country individually and combined across countries in a meta-analysis.

Results

Study population and preterm and stillbirth rates

We included 52,067,596 births occurring between January 2015 and July 2020. Of these, 51,340,025 (98.6%) were from the 18 population-based datasets capturing whole countries or regions and 727,571 (1.4%) were from the 26 non-population-based datasets (Supplementary Table 1). A total of 3,115,628 births were from the lockdown period, that is, the first four months after the stringency score first exceeded 50 on the Oxford COVID-19 Government Response Tracker Lockdown Stringency Index (henceforth 'Oxford Stringency Index'³⁸). As described in Supplementary Table 2 and Supplementary Fig. 1, non-population-based datasets from five countries were excluded from the analysis due to data availability and quality issues. Lockdowns remained above the threshold of 50 on the Oxford Stringency Index in most countries throughout the four month lockdown period used in this study, apart from Finland, Iceland, Norway and Switzerland (Supplementary Fig. 2).

As shown in Table 1, among population-based datasets, the preterm birth rates (<37 weeks gestation) across the study period ranged from 5.8% (Finland) to 11.8% (Brazil); very preterm birth rates (<32 weeks gestation) from 0.8% (Finland and Peru) to 2.0% (Brazil); spontaneous preterm birth rates from 2.8% (New South Wales, Australia) to 9.2% (Brazil); and stillbirths from 2.5 per 1,000 births (Finland) to 10.4 per 1,000 births (Brazil). Temporal trends in preterm birth rates for each country are shown in Fig. 1, with equivalent plots for very preterm, spontaneous preterm birth and stillbirth rates in Extended Data (Extended Data Figs. 1–3). In the non-population-based data, there was wide variation in preterm and stillbirth rates both within and between countries (Table 2 and Supplementary Figs. 3–12).

Data quality

Data quality was generally high in the population-based datasets, with most having <1% missing data on gestational age and <5% difference in observed versus expected total number of births during the lockdown period (Table 1). Among non-population-based datasets, there were low levels of missing data on gestational age (<1%) in datasets from Asia, Europe, North America and Latin America; however, some datasets from sub-Saharan Africa had substantial (up to 21%) missing information on gestational age. In addition, the total number of observed births differed by >10% (either increase or decrease) from expected during the lockdown period in some non-population-based datasets (Hong Kong, Poland and in some facilities in Ghana, Kenya and Nigeria) (Table 2). These quality issues among non-population-based datasets support our a priori decision to focus the primary analyses on population-based datasets.

Association between lockdown and preterm birth

Figure 2 shows the country-specific OR for the impact of lockdown on preterm birth, for each month of lockdown (additional detailed plots: Supplementary Figs. 13–16). In the first month, for example, the OR for the impact of lockdown on preterm birth ranged from 0.87 in Iran (95% CI 0.78–0.98) to 1.24 in Iceland (95% CI 0.71–2.16). Our meta-analysis of population-based data indicated small reductions in preterm birth in the first (OR 0.96, 95% CI 0.95–0.98, $P < 0.001$), second (OR 0.96, 95% CI 0.92–0.99, $P = 0.03$), and third month (OR 0.97, 95% CI 0.94–1.00, $P = 0.09$) of lockdown, but none in the fourth month (OR 0.99, 95% CI 0.96–1.01, $P = 0.34$) (Figs. 2 and 3). Between-country heterogeneity (I^2) was 0%, 64%, 53% and 34% for the first to fourth month of lockdown, respectively. Stratifying by country income level indicated similar reductions in the odds of preterm birth for both high and upper-middle-income country settings, with higher between-country heterogeneity among upper-middle-income countries (Fig. 3).

There was a wider range of ORs across the non-population-based data with, for example in the first month of lockdown, ORs of 0.38 (95% CI 0.17–0.87) in one facility in Nigeria, and up to 1.91 (95% CI 0.97–3.76) in another facility in Nigeria (Extended Data Fig. 4 and Supplementary

Table 1 | Data availability, overall preterm; very preterm; spontaneous preterm and stillbirth rates for population-based datasets, and data quality from 2015 to 2020 (exact timeframes vary by country as outlined in Supplementary Table 1)

	Total number of births included	Monthly number of births, average	Preterm births (%)	Very preterm births (%)	Spontaneous preterm births (%)	Stillbirths per 1,000 births	Data quality	
							Observed versus expected total number of births during lockdown ^d (%)	Births missing gestational age (%)
Population-based data								
Asia-Pacific								
Australia, New South Wales ^a	518,281	7,853	6.4	0.9	2.8	3.4	-1%	0.1
Middle East and North Africa								
Iran	4,852,267	112,843	8.7	1.6	No data	7.9	+2%	0
Europe								
Belgium	665,086	10,077	8.6	1.5	6.0	6.1	No difference	0.02
Denmark, Central Region	66,481	1,231	6.0	1.0	No data	Not included ^e	No difference	1.3
Finland	278,376	4,155	5.8	0.8	3.6	2.5	No difference	0.2
Hungary	501,860	7,604	8.8	1.5	No data	4.4	+3%	0.02
Iceland	23,463	350	6.4	0.9	2.9	2.7	-5%	0.5
Norway	316,067	4,789	6.4	1.0	3.6	3.3	-1%	0.2
Scotland ^b	288,118	4,300	8.6	1.3	4.4	4.1	-1%	0.3
Sweden	586,914	8,892	6.2	1.0	5.0	3.6	+3%	0
Switzerland	486,357	7,259	7.2	1.2	No data	4.1	+1%	0.03
Wales ^a	176,964	2,641	8.1	1.4	3.4	4.4	-5%	0.4
North America								
Canada	1,610,511	24,037	8.3	1.1	5.0	6.4	-2%	0.6
United States ^c	20,979,669	313,129	9.9	1.5	4.6	No data	-1%	0.1
Latin America and Caribbean								
Brazil	16,356,490	244,127	11.8	2.0	9.2	10.4	-8%	2.4
Chile ^c	1,244,121	18,567	8.5	1.3	8.4	No data	-5%	0.3
Peru ^c	2,156,486	39,935	6.6	0.8	No data	No data	-7%	0.001
Uruguay	232,514	3,523	9.5	1.5	No data	No data	+8%	1.3

^aIncludes only births from 24 weeks onwards. ^bIncludes only births from 28 weeks onwards in the calculation for spontaneous preterm birth rates (as it is not possible to classify foetal losses at 22 and 23 weeks gestation as spontaneous or indicated). ^cIncludes only live births. ^dAscertained by comparing the observed total number of births in the lockdown period with the forecasted total number of births calculated using a Poisson time series, which accounted for preceding seasonal and yearly trends. ^eNot included due to high levels of suppressed data.

Fig. 17). There was no evidence for an association between lockdown and preterm birth in the meta-analysis of the non-population-based data (Fig. 3, Extended Data Fig. 4 and Supplementary Figs. 17–20).

For very preterm births, there was no evidence of an impact of lockdown over the four months of lockdown (Fig. 4, Extended Data Figs. 5 and 6 and Supplementary Figs. 21–28), with ORs for all population-based datasets varying between 1.00 and 1.02 and CIs spanning the null value. For spontaneous preterm births, in the subset of countries with data available, there were small relative decreases (3–4%) in the first three months following lockdown in HICs, but not in Brazil, the only upper-middle-income country providing these data (Fig. 5, Extended Data Fig. 7 and Supplementary Figs. 29–32). There was also evidence for a decrease in the fourth month of lockdown using only the non-population-based data (OR 0.88, 95% CI 0.78–0.99, $P = 0.04$, $I^2 = 0\%$) (Fig. 5, Extended Data Fig. 8 and Supplementary Figs. 33–36).

Association between lockdown and stillbirths

The OR for the impact of lockdown on stillbirth ranged from 0.80 in Finland (95% CI 0.34–1.91) to 1.35 in New South Wales, Australia (95% CI 0.93–1.96) in the population-based data in the first month of lockdown (Extended Data Fig. 9 and Supplementary Fig. 37). In the meta-analysis

of the population-based datasets, we found no clear evidence of an impact of lockdown on stillbirth in the first month of lockdown overall (OR 1.04, 95% CI 0.99–1.09, $P = 0.10$, $I^2 = 0\%$), but an increase was observed when restricting to HICs (OR 1.14, 95% CI 1.02–1.29, $P = 0.02$, $I^2 = 0\%$), driven by Canada (OR 1.26, 95% CI 1.04–1.51, $P = 0.02$) (Fig. 6, Extended Data Fig. 9 and Supplementary Fig. 37). There was an increase in the odds of stillbirth across all population-based datasets in the second (OR 1.07, 95% CI 1.02–1.12, $P = 0.001$, $I^2 = 0\%$), third (OR 1.08, 95% CI 1.02–1.13, $P = 0.004$, $I^2 = 0\%$) and possibly fourth month (OR 1.07, 95% CI 1.00–1.15, $P = 0.07$, $I^2 = 11\%$) of lockdown. These ORs were driven largely by Brazil (Extended Data Fig. 9 and Supplementary Figs. 38–40), and when we restricted the meta-analysis to HICs only, we found no evidence for an association between lockdown and stillbirth in the second month (OR 1.00, 95% CI 0.88–1.12, $P = 0.98$, $I^2 = 0\%$), third month (OR 0.99, 95% CI 0.88–1.12, $P = 0.89$, $I^2 = 0\%$) and fourth month (OR 1.01, 95% CI 0.87–1.18, $P = 0.86$, $I^2 = 13\%$) of lockdown (Fig. 6).

In the non-population-based data, the ORs for stillbirth in the first month of lockdown ranged from 0.24 in a facility in Nigeria (95% CI 0.08–0.69) to 3.20 in a facility in Poland (95% CI 0.61–16.74) (Extended Data Fig. 10 and Supplementary Fig. 41).




Fig. 1 | Trends in preterm birth rates among population-based datasets included in the iPOP Study; 2015–2020. Observed rates of preterm birth (among all births 22 weeks onwards) over time (2015–2020) for countries providing population-based data, with the forecasted preterm birth rates and 95% CIs also plotted for the lockdown period. Lockdown period shown in shaded grey. Unless specified otherwise, preterm birth rates are the percentage of all births from 22 weeks onwards that were born before 37 weeks gestation. Left:

entire study period (2015–2020) illustrating seasonality and trends over time. Right: 2020 period enlarged to show the observed and forecasted births during lockdown. Forecasted ('modelled') rates were estimated from a 'pre-lockdown model' that was used to forecast the expected rates of the preterm birth for each of the first four months of lockdown assuming lockdown had not occurred. *Preterm birth rates restricted to births from 24 weeks onwards; **Preterm birth rates restricted to live births only.

Table 2 | Data availability, overall preterm; very preterm; spontaneous preterm and stillbirth rates for non-population-based datasets included in the iPOP Study, and data quality from 2015 to 2020 (exact timeframes vary by country as outlined in Supplementary Table 1)

	Total number of births included	Monthly number of births, average	Preterm births (%)	Very preterm births (%)	Spontaneous preterm births (%)	Stillbirths per 1,000 births	Data quality	
							Observed versus expected total number of births during lockdown ^b (%)	Births missing gestational age (%)
Hong Kong								
All public facilities (pooled)	199,134	3,064	8.4	1.4	No data	4.2	-13%	0
Australia, Queensland								
Facility 1	58,204	869	10.6	2.5	4.6	5.7	-2%	0
Matlab, Bangladesh								
Demographic surveillance area ^a	29,705	443	13.5	1.6	13.5	15.6	+7%	0.3
Poland								
Facility 1	8,287	126	7.0	0.3	4.9	4.1	-20%	0
Facility 2	42,243	640	15.6	4.4	13.5	8.8	-13%	0.2
Washington State, United States								
14 facilities (pooled)	90,586	2,107	10.0	1.7	6.3	4.2	+10%	0
Mexico City, Mexico								
Facility 1	10,084	235	28.9	6.0	10.8	51.0	+10%	0.8
Ghana								
Facility 2	12,452	290	21.3	9.5	11.9	17.5	+8%	17.7
Facility 3	7,724	188	24.5	14.2	9.6	20.5	+8%	6.2
Facility 4	8,450	197	25.3	13.9	11.5	18.1	+4%	9.3
Facility 5	13,208	194	24.2	14.4	9.1	20.6	+6%	6.1
Facility 6	13,325	333	24.1	8.5	13.6	17.7	-18%	21.3
Facility 7	15,818	406	19.1	6.2	10.6	20.0	+17%	13.9
Facility 9	15,473	360	19.8	7.7	11.0	17.5	+1%	17.1
Kenya								
Facility 1	34,773	527	4.0	1.4	No data	20.4	+5%	1.7
Facility 3	51,790	909	3.3	0.7	No data	13.3	-32%	0.6
Nigeria								
Facility 1	7,275	110	22.2	7.4	6.7	49.2	-6%	0.2
Facility 2	6,923	107	15.4	3.2	14.2	41.5	+1%	1.7
Facility 3	12,118	181	8.4	0.2	6.8	42.4	-11%	17.1
Facility 4	5,267	79	16.2	5.6	15.5	45.0	+6%	3.4
Facility 8	8,808	131	7.2	1.5	No data	55.1	-1%	8.0
Facility 9	7,252	110	16.0	4.2	No data	59.0	-10%	9.3
Facility 10	17,457	265	16.1	3.4	6.8	106.9	+22%	3.1
Facility 11	10,361	155	21.6	7.4	No data	77.1	-55%	6.3
Facility 12	14,479	216	9.4	2.4	5.7	54.2	+1%	2.5
Uganda								
Facility 2	26,375	394	9.5	3.3	3.0	16.2	+2%	1.6

^aIncludes only births from 28 weeks onwards for stillbirths. ^bAscertained by comparing the observed total number of births in the lockdown period with the forecasted total number of births calculated using a Poisson time series, which accounted for preceding seasonal and yearly trends.

We observed increased odds of stillbirth for the third and fourth months of lockdown in the meta-analysis of non-population-based data with relatively low levels of between-study heterogeneity at 0% and 18%, respectively (Fig. 6, Extended Data Fig. 10 and Supplementary Figs. 41–44); however, CIs were wide and included the null value.

Sensitivity analyses

Sensitivity analysis of the population-based data restricting the analysis to only live births (Supplementary Table 3) and restricting to only births from 28 weeks gestation onwards (Supplementary Table 4) led to negligible changes in the country-specific estimates of the impact of lockdown on preterm birth rates. Similarly, excluding data from




Fig. 2 | Association between lockdown and preterm birth rates in the iPOP Study in population-based datasets. Individual and pooled population-based estimates of the association between lockdown and the odds of preterm birth among all births 22 weeks onwards, stratified by time since lockdown. Individual country ORs (represented by boxes on plot) were calculated by comparing the observed odds of preterm birth with the forecasted odds of preterm birth from

an ITS model that was fitted to pre-lockdown data. Horizontal lines surrounding each box on the forest plot are 95% CIs. Arrows indicate upper and/or lower bounds of the CI that are outside the x-axis limits. Pooled ORs (represented by diamonds on plot) for the association between lockdown and the odds of preterm birth were calculated using random-effects meta-analysis. Sample sizes for each country provided in Table 1. *Births from 24 weeks onwards **Live births only.




Fig. 3 | Pooled estimates of the association between lockdown and preterm birth rates in the iPOP Study. Pooled ORs capturing the association between lockdown and the odds of preterm birth, stratified by month of lockdown, type of data (population-based, non-population based) and income setting. Pooled

ORs (represented by boxes on plot) were calculated using random-effects meta-analysis. Horizontal lines surrounding each box on the forest plot are 95% CIs for the OR. Arrows indicate upper and/or lower bounds of the CI that are outside the x-axis limits.




Fig. 4 | Pooled estimates of the association between lockdown and very preterm birth in the iPOP Study. Pooled ORs capturing the association between lockdown and the odds of very preterm birth (births at <32 weeks gestation), stratified by month of lockdown, type of data (population-based,

non-population-based) and income setting. Pooled ORs (represented by boxes on plot) were calculated using random-effects meta-analysis. Horizontal lines surrounding each box on the forest plot are 95% CIs for the OR.




Fig. 5 | Pooled estimates of the association between lockdown and spontaneous preterm birth in the iPOP Study. Pooled ORs capturing the association between lockdown and the odds of spontaneous preterm birth, stratified by month of lockdown, type of data (population-based, non-population

based) and income setting. Pooled ORs (represented by boxes on plot) were calculated using random-effects meta-analysis. Horizontal lines surrounding each box on the forest plot are 95% CIs for the OR. Arrows indicate upper and/or lower bounds of the CI that are outside the x-axis limits. NA, not applicable.

Brazil and the United States, which together contributed slightly over 70% of the births included in the study, from the meta-analysis of the ORs for the association between lockdown and preterm birth among population-based datasets led to negligible changes in our estimates (Supplementary Table 5).

Discussion

In this international study, we have reported on the impact of pandemic-related lockdowns on preterm birth and stillbirth. We included over 52 million births from 26 countries, largely derived from 18 population-based datasets from HICs and upper-middle-income countries. We observed small (3–4%) relative reductions in the overall rates of preterm birth following lockdown, although with some variation among countries. Reductions in spontaneous preterm birth rates were observed in HICs only, and no change in very preterm birth was observed. The observed decrease in preterm births did not appear to be driven by a reciprocal increase in stillbirth rates in HICs. We did, however, find evidence for increases in stillbirth in Brazil in the second, third and fourth months of lockdown. It remains plausible that some reduction in preterm birth rates was linked to increased stillbirth rates in HICs, but we had limited power to detect this due to the relatively small number of stillbirths. Our patient partners' interpretation of these results are provided in Supplementary Discussion.

Multiple studies have assessed the effects of pandemic lockdowns on perinatal outcomes following initial reports of dramatic reductions in preterm birth rates^{8,10,11}, and several meta-analyses have been conducted^{25–27}. However, there have been important differences in data quality across prior studies, many of which did not apply analytical approaches that could account for pre-pandemic trends in perinatal outcomes²⁸. Notably, few studies have included both preterm birth and stillbirth rates, despite the importance of considering perinatal outcomes together^{39,40}. Our findings provide evidence by applying an ITS design to high-quality population-based data from 18 countries, and evaluating potentially competing outcomes (that is, preterm birth and

stillbirth) in parallel. Even though we used the same analytical approach across data from different countries, between-country differences in the association between lockdown and both preterm birth and stillbirth rates were seen. These could be driven by contextual differences in the implementation of lockdown and differences in the impact of lockdown, which in turn may be driven by the resilience of health or social systems.

Lockdowns had important and diverse impacts on several exposures known to influence preterm birth, offering some possible explanations for the small reductions observed in our study. For spontaneous preterm birth, although the aetiology is poorly understood, putative mediating factors include reductions in air pollution and, in particular, non-COVID infections, both of which were shown to decline across a diverse range of countries, albeit to varying degrees^{32,35,41}. It is possible that a reduction in physician-initiated preterm births also contributed to the overall reduction in preterm birth in some settings^{6,42}, although we could not investigate this directly, as data on medically indicated preterm births were not available for all countries and could not be reliably inferred. The increase in stillbirth with lockdown in some countries might reflect reduced access to timely quality antenatal and intrapartum care⁴³. As our findings represent the average impact of lockdown across populations, we cannot differentiate the relative contribution of specific factors, nor whether the impact of lockdown differed between specific population subgroups. For example, an increased risk of preterm birth in some women (for example, due to reduced access to care) might have been offset at the population level by public health responses reducing other risk factors, such as air pollution and infectious diseases other than COVID-19.

Using aggregate data, it was not possible to distinguish the impacts of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from those of pandemic-related restrictions. Relative to the essentially universal exposure of all pregnant women to lockdowns, only a small fraction¹⁹ experienced SARS-CoV-2 infection at this early stage of the pandemic. As SARS-CoV-2 infection increases the risk of both preterm birth and stillbirth^{44–46}, it is possible that our




Fig. 6 | Pooled estimates of the association between lockdown and odds of stillbirth in the iPOP Study. Pooled ORs capturing the association between lockdown and the odds of stillbirth, stratified by month of lockdown, type of data (population-based, non-population based) and income setting. Pooled ORs

(represented by boxes on plot) were calculated using random-effects meta-analysis. Horizontal lines surrounding each box on the forest plot are 95% CIs for the OR. Arrows indicate upper and/or lower bounds of the CI that are outside the x-axis limits.

results have underestimated the impact of lockdown on preterm birth and overestimated the impact on stillbirth, although any influence would be minimal given the relatively much smaller proportion of women experiencing infection compared with the broader effects of lockdown.

Our results highlight the paucity of population-based data in many settings, and the challenges of interpreting non-population-based data to assess changes in perinatal outcomes over time. First, in some countries, we observed large variation in preterm birth and stillbirth rates between facilities. These might reflect differences in case mix as well as challenges in accurate reporting of key variables, particularly in estimating gestational age when routine antenatal ultrasound is unavailable. Second, some facilities within the same country documented markedly different impacts of lockdown on preterm birth and stillbirth rates. In some countries, there were dramatic shifts in how and where pregnant women accessed intrapartum care¹⁴, urging caution in the interpretation of results from studies of single facilities. In addition, the paucity of population-based data in LMICs—where the majority of preterm births and stillbirths occur^{30,47,48}—was striking. We made extensive efforts to identify high-quality data from across different country income levels, including iterative development of the data collection tools with groups from a range of different countries and, in consideration of the more intensive data preparation required in some countries to harness data on perinatal outcomes, special funding allocations to support the preparation of data from LMIC settings. While there have been substantial efforts globally to improve perinatal data and outcomes through stillbirth and preterm birth prevention initiatives, such as Every Newborn Action Plan⁴⁹ and parent-led global organizations such as the International Stillbirth Alliance⁵⁰, we echo previous calls for the urgent need to develop systems that routinely capture high-quality data on perinatal outcomes with standardized definitions across countries^{51,52}.

The strengths of our study include the broad global coverage, use of pre-defined and internationally recognized outcome measures, and

analytical approaches to account for time trends and seasonal patterns in perinatal outcomes⁵³, as well as differentiation between population and non-population-based data and country income settings.

We acknowledge several limitations. First, we defined onset of lockdown as the month during which a country first exceeded 50 on the Oxford Stringency Index³⁸. This is a crude measure to approximate the severity of pandemic-related restrictions in each country as a whole; it does not reflect within-country variations or individual experiences in lockdown measures. The Oxford Stringency Index also does not capture variations in access to maternity and healthcare nor provide information on the extent to which restrictions were enforced or followed. This is likely to be particularly problematic for large countries such as Brazil and the United States, but, unfortunately, subnational data on perinatal outcomes were not available for this study. Second, ITS analyses are vulnerable to confounding by unmeasured events occurring simultaneously to the intervention that might also impact the outcomes. Third, we used aggregate data and could not differentiate within-population differences on the impact of lockdown measures, which is likely to vary by socio-economic status, region and age. Fourth, as we focused on the association between lockdown and perinatal outcomes for the first four months following the lockdowns in response to the first wave of COVID-19, we mainly captured the potential impact of lockdown on pregnancies that were in their third trimester at the start of lockdown; further studies should be conducted to assess whether there was an association between lockdown and perinatal outcomes for pregnancies that were at earlier gestations in lockdown. Fifth, where we found no evidence for an association (for example, for stillbirth, very preterm birth and spontaneous preterm birth in all or some settings), we cannot rule out that there was no change as these were relatively rare with wide CIs. The use of equivalence tests to formally test whether there was no evidence for a clinically meaningful change in our outcomes was considered but ultimately not conducted as there is no minimum clinically meaningful difference for stillbirth or preterm births, with

any change being of interest. Finally, the interpretation of our results is limited by difficulties with data capture, population coverage and data quality from some countries. We therefore conducted separate analyses for population-based data considered to be of high quality, yielding more robust estimates.

In summary, this international study provides evidence on global changes in preterm birth and stillbirth across 26 countries during the initial COVID-19 pandemic lockdowns. Overall, we observed a 3–4% relative reduction in the preterm birth rate during the first three months of lockdown based on population-based data from HICs and upper-middle-income countries. This decrease in preterm births did not appear to be linked with an increase in stillbirths in most settings. Consistent evidence of an increase in stillbirths was only observed in Brazil following lockdown, the causes of which certainly warrant further exploration. Although relatively small, the observed changes in preterm birth are meaningful at the population level: assuming the observed decline during lockdown is real and consistent worldwide, our findings suggest that nearly 50,000 preterm births (or approximately four per 1,000 live births) were averted in the first month of lockdown alone, based on a global pre-pandemic preterm birth rate of 10.6% (ref. 1). Understanding the underlying pathways linking lockdown with the reduction in preterm births could have implications for clinical practice and policy. Our study also highlights the need to develop further capacity for high-quality and appropriate standardized data collection in LMICs⁵⁴. Finally, the iPOP platform offers novel opportunities to rapidly conduct harmonized perinatal health research globally during the COVID-19 pandemic and beyond.

Methods

We engaged with national and subnational data custodians to standardize and analyse aggregate-level data on monthly numbers of births stratified by gestational age from population-based data sources, and to conduct exploratory analyses using non-population-based data sources. Detailed time-series data enabled us to use pre-lockdown trends in preterm birth and stillbirth rates to forecast the expected trend in these outcomes had lockdown not occurred, and compare these forecasted rates with the observed rates for each country individually and combined across countries in a meta-analysis. The study was conducted using a common protocol⁵⁵ and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline⁵⁶.

Ethical considerations

Contributors from countries where the data were not publicly available obtained ethics approval from their respective institutional review boards (Supplementary Table 6). We did not seek ethical approval for publicly available data sources (Supplementary Table 6). All data contributors completed a Data Contribution Agreement, which outlined the terms and conditions for uploading and storing data to the SAIL Databank⁵⁷.

Study data and population

We collected aggregate data from 26 countries (Supplementary Table 1). We considered data sources as population-based if they captured more than 90% of births in the region or country, and non-population-based if coverage was $\leq 90\%$. There were 18 national and regional population-based data sources that, where possible, included all recorded births from 22 + 0 weeks gestation between January 2015 and July 2020. Births recorded as $\geq 45 + 0$ weeks gestation were censored as unfeasible gestation of birth. Data were also included in the analyses if they were available for a shorter pre-pandemic period (Denmark, Iran and Peru), for live births only (Chile, Peru and the United States), or used a slightly different cut-off for the lower limit of gestational age ($\geq 24 + 0$ weeks gestation in New South Wales, Australia and Wales, UK).

Data available from low- and lower-middle-income country settings were exclusively non-population-based, and we therefore included non-population-based data as part of the main analysis in a deviation from the original protocol⁵⁵, to provide insights across a range of countries by income levels. There were 26 non-population-based data sources from ten countries, which included data from individual health facilities (23 datasets from seven countries), pooled data from a group of health facilities (two datasets from two countries) and demographic surveillance sites (one dataset from one country) (Supplementary Table 1). For Australia and the United States, there were both population-based and non-population-based data sources included in the analysis; the data sources from Australia covered different regions of the country whereas data sources for the United States covered some overlapping regions but were not included together in any analysis (as described below).

To ensure data and measures from different settings were comparable, consistent and coherent, we developed a detailed protocol, including standardized outcome definitions and data collection templates⁵⁵, and stored and analysed the standardized data in the Secure Anonymized Information Linkage (SAIL) Databank. We collected information on national income levels from the World Bank⁵⁸ (Supplementary Table 1). In our study protocol⁵⁵, we proposed to additionally collect national-level data on air pollution, adherence to lockdown, COVID-19 rates, world region and parental leave policy; we did not ultimately include these data due to (1) not being able to identify readily available reliable data for all our study settings (air pollution and adherence to lockdown) or (2) finding little or no variation between the included datasets beyond that captured by country-income level (COVID-19 rates, world region and parental leave policy).

Defining lockdown

For each country, we defined the start of lockdown using the Oxford Stringency Index³⁸. In brief, this index collects information on different social, health and economic government policies instituted in response to the COVID-19 pandemic.

We considered the onset of a country's initial lockdown as the date at which the stringency score first exceeded 50 on the Oxford Stringency Index (range 0–100). This cut-off was pre-specified in the study protocol and based on expert advice. For dates of lockdown that occurred between the 1st and 15th of the month, the first month of lockdown was assigned to that month; for dates after the 15th, the first month of lockdown was assigned to the following month. As described below, we explored the impact on perinatal outcomes in the first four months from a country's initial lockdown, regardless of whether the Oxford Stringency Index dropped below 50 during this time. We restricted the analysis to the first four months to facilitate comparison between different countries included in this study; this was when the strictest lockdowns were in place in response to the first wave of COVID-19, with increasing variability between countries beyond this timeframe.

Defining perinatal outcomes

Data contributors recorded monthly numbers of births categorized into pre-specified gestational age groups, according to our data collection template. The outcome definitions aligned with global standard definitions for preterm birth and stillbirth^{59,60} and were developed in consultation with our international collaborators to ensure that all data contributors captured these outcomes consistently.

For each month, we calculated the preterm birth rate per 100 births, as the number of births from 22 + 0 to 36 + 6 weeks gestation divided by the total number of births⁶¹. We calculated the very preterm birth rate per 100 births as the number of births from 22 + 0 to 31 + 6 weeks gestation divided by the total number of births. We estimated the spontaneous preterm birth rate per 100 births as the number of births from 22 + 0 to 36 + 6 weeks gestation with spontaneous

onset divided by the total number of births. The preterm, very preterm and spontaneous preterm birth rates were calculated, where available, using all births and live births only for settings where data on stillbirths were not available. We were not prescriptive in how data contributors should identify and define spontaneous births, beyond specifying that these should capture births preceded by spontaneous contractions or preterm prelabour rupture of membranes. Further details of the methods used to estimate gestational age across the different datasets are provided in Supplementary Table 1. The stillbirth rate was expressed per 1,000 births and calculated by dividing the number of stillbirths occurring from $\geq 22 + 0$ weeks gestation by the total number of births.

Data analysis

A detailed description of the steps to clean and prepare the data before undertaking the analysis is provided in Supplementary Methods. In brief, we evaluated data quality and completeness of each dataset by: (1) assessing data completeness, including calculating the percentage of births missing gestational age; (2) examining for outliers in perinatal outcome rates; and (3) assessing whether there was any evidence for a change in the documented number of births after lockdown which, given the early stage of the pandemic when fertility will not have been affected, would suggest that women were giving birth in different locations or there were changes in recording practices (further details on analytical procedures in Supplementary Methods). Any population-based datasets where there was a relative change of a 10% or more increase or decrease in the number of observed compared with expected total births following lockdown were excluded from the population-based analysis, and analysed as a non-population-based dataset.

For each country-specific population-based dataset, we undertook an ITS analysis⁶² to model the effect of lockdown on perinatal outcomes. First, we fitted weighted ITS models on the entire time series of the monthly log(odds) of the outcomes. Weights were based on the total number of births per month; imputed values for missing data (Supplementary Methods) were down-weighted to one (minimum possible number of births) to reduce bias from missing observations. Models accounted for seasonality (with inclusion of month as a fixed effect) and long-term temporal trends, and we allowed the within-period trend and intercept to be different for the pre-lockdown and lockdown periods. Given that countries could have different trends in perinatal outcomes, we fitted five different potential models for each outcome for each country evaluating the trend as a linear, square, quadratic, logarithmic and second-order polynomial effect. The model with the lowest Akaike Information Criterion was chosen as the best fit model⁶³. We assessed the goodness of fit of the best model by examining the standardized residuals. Second, to compare the forecast of the best fit model to the post-lockdown observed values, we refitted the model to the pre-lockdown observations using the same trend effect selected through the Akaike Information Criterion. This 'pre-lockdown model' was then used to forecast the expected rates of the perinatal outcomes for each of the first four months of lockdown assuming lockdown had not occurred. Plots of the observed and forecasted rates were used to visualize trends in outcomes over time. We calculated the OR between the observed odds and the forecast odds of each perinatal outcome for each of the first four months of lockdown, a time period chosen to capture when lockdowns in response to the first wave of COVID-19 were implemented. We specified a priori to analyse each of the first four months of lockdown separately, as we hypothesized that the association between lockdown and perinatal outcomes would vary by month of lockdown given how rapidly public health measures evolved during this time. To analyse the non-population-based data, we used a linear regression model (rather than an ITS model) to forecast the log(odds) of perinatal outcomes in the first to fourth month of lockdown assuming lockdown had not occurred. This was due to non-population based datasets varying in data availability with respect to the pre-lockdown

study period, frequency of reporting of outcomes, and degree of missingness. To capture changes by season and annual trends pre-lockdown in our forecasted estimates, the model included month (categorical) and year (continuous), with year also included as a squared term to account for settings with non-linear changes in the perinatal outcome rates over time. We then calculated the OR quantifying the impact of lockdown on the perinatal outcomes by dividing the observed odds of each perinatal outcome by the forecasted odds for each of the first four months of lockdown.

The ORs from each dataset for each perinatal outcome at each month after lockdown were pooled using random-effects meta-analysis⁶⁴, and this was done separately for the population-based data and the non-population-based data. For the population-based data, we stratified the meta-analysis by country income level (where sufficient datasets for each category permitted): high income versus upper-middle income. For non-population-based data, we used a three-level meta-analysis model to account for the dependency of observations of the impact of lockdown between facilities in the same country⁶⁵. The I^2 statistic, which captures the percentage of the variability in the ORs between countries that is due to heterogeneity rather than sampling error, was used to assess for evidence of between-country heterogeneity in the ORs⁶⁶. We did not conduct equivalence tests to assess whether there was evidence that there was no association between the pandemic and our outcomes, as these tests require identifying a minimum clinically significant difference below which we would conclude that there was no change in our outcomes. There is no clear clinically significant difference that can be used for preterm birth or stillbirth, with any increase being of concern. Where relevant, we report P values for the probability of observing a relative difference in our outcomes at least as big as that in our data under the assumption that there was no association between the pandemic and our outcomes.

All analyses were performed in R version 4.1.1.

Sensitivity analyses

We conducted three sensitivity analyses. First, to assess the potential impact of including datasets that only provided data on preterm birth among live births (rather than all births, 3/18 datasets) in the main analysis, we conducted ITS analysis restricted to live births among datasets which also provided data on all births ($n = 15$ datasets). Second, to evaluate the impact of including datasets with a different lower limit for gestational age in the main population-based analysis for preterm birth, we restricted the time-series analysis to births from 28 weeks gestational age onwards, the lower threshold recommended by the World Health Organization for international comparisons⁶⁰. Third, we also conducted a sensitivity analysis for our meta-analysis of the association between lockdown and preterm birth among all population-based datasets, excluding Brazil and the United States, which together contributed slightly over 70% of the births included in the study.

Public and patient involvement

Parent representatives from four national patient partner organizations were included from the inception of the iPOP study to inform the common goal of timely implementation of quality research. We used mechanisms to ensure meaningful collaboration through inclusion on meeting agendas and facilitating meeting processes so that everyone had an equal voice to ensure patient partners were treated with mutual respect. Patient partners from Brazil, Canada, Hungary and Ireland co-developed the iPOP protocol, attended all iPOP meetings to ensure meaningful collaboration, edited and provided input to this manuscript, and are continuing to co-build meaningful and innovative knowledge translation strategies.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

This study makes use of anonymized data held in the Secure Anonymised Information Linkage (SAIL) Databank. We would like to acknowledge all the data providers who made anonymized data available for research (listed in Supplementary Table 1). The responsibility for the interpretation of the information SAIL supplied is the authors' alone. Data may be available to researchers for analysis after securing relevant permissions from the data contributors and the databank in which the data are held (SAIL Databank). The approvals process is managed by application to the SAIL Databank who hold data sharing agreements with the data providers. Restricted datasets may require additional approvals from data custodians and ethical authorities in the relevant country/setting. Enquiries for data access should be made using the contact form at <https://saildatabank.com/contact>, or by making an enquiry to ICODA at <https://icoda-research.org/contact/>.

Code availability

Custom code that supports the findings of this study is available from the corresponding author Sarah Stock (sarah.stock@ed.ac.uk) upon request.

References

- Chawanpaiboon, S. et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *Lancet Glob. Health* **7**, e37–e46 (2019).
- Vogel, J. P. et al. The global epidemiology of preterm birth. *Best. Pract. Res. Clin. Obstet. Gynaecol.* **52**, 3–12 (2018).
- Blencowe, H. et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. *Lancet Glob. Health* **4**, e98–e108 (2016).
- Hug, L. et al. Global, regional, and national estimates and trends in stillbirths from 2000 to 2019: a systematic assessment. *Lancet* **398**, 772–785 (2021).
- Matheson, A. et al. Prematurity rates during the coronavirus disease 2019 (COVID-19) pandemic lockdown in Melbourne, Australia. *Obstet. Gynecol.* **137**, 405–407 (2021).
- Gallo, L. A. et al. A decline in planned, but not spontaneous, preterm birth rates in a large Australian tertiary maternity centre during COVID-19 mitigation measures. *Aust. N. Z. J. Obstet. Gynaecol.* <https://doi.org/10.1111/ajo.13406> (2021).
- Justman, N. et al. Lockdown with a price: the impact of the COVID-19 pandemic on prenatal care and perinatal outcomes in a tertiary care center. *Isr. Med. Assoc. J.* **22**, 533–537 (2020).
- Hedermann, G. et al. Danish premature birth rates during the COVID-19 lockdown. *Arch. Dis. Child. Fetal Neonatal Ed.* **106**, 93–95 (2020).
- McDonnell, S., McNamee, E., Lindow, S. W. & O'Connell, M. P. The impact of the Covid-19 pandemic on maternity services: a review of maternal and neonatal outcomes before, during and after the pandemic. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **255**, 172–176 (2020).
- Been, J. V. et al. Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study. *Lancet Public Health* **5**, e604–e611 (2020).
- Philip, R. K. et al. Unprecedented reduction in births of very low birthweight (VLBW) and extremely low birthweight (ELBW) infants during the COVID-19 lockdown in Ireland: a 'natural experiment' allowing analysis of data from the prior two decades. *BMJ Glob. Health* **5**, e003075 (2020).
- De Curtis, M., Villani, L. & Polo, A. Increase of stillbirth and decrease of late preterm infants during the COVID-19 pandemic lockdown. *Arch. Dis. Child. Fetal Neonatal Ed.* <https://doi.org/10.1136/archdischild-2020-320682> (2020).
- Einarsdóttir, K., Swift, E. M. & Zoega, H. Changes in obstetric interventions and preterm birth during COVID-19: a nationwide study from Iceland. *Acta Obstet. Gynecol. Scand.* **100**, 1924–1930 (2021).
- Kc, A. et al. Effect of the COVID-19 pandemic response on intrapartum care, stillbirth, and neonatal mortality outcomes in Nepal: a prospective observational study. *Lancet Glob. Health* **8**, e1273–e1281 (2020).
- Briozzo, L., Tomasso, G., Viroga, S., Nozar, F. & Bianchi, A. Impact of mitigation measures against the COVID 19 pandemic on the perinatal results of the reference maternity hospital in Uruguay. *J. Matern. Fetal. Neonatal Med.* **35**, 5060–5062 (2021).
- Main, E. K. et al. Singleton preterm birth rates for racial and ethnic groups during the coronavirus disease 2019 pandemic in California. *Am. J. Obstet. Gynecol.* **224**, 239–241 (2020).
- Wood, R. et al. Preterm birth during the coronavirus disease 2019 (COVID-19) pandemic in a large hospital system in the United States. *Obstet. Gynecol.* **137**, 403–404 (2021).
- Arnaez, J. et al. Lack of changes in preterm delivery and stillbirths during COVID-19 lockdown in a European region. *Eur. J. Pediatr.* **180**, 1997–2002 (2021).
- Pasternak, B. et al. Preterm birth and stillbirth during the COVID-19 pandemic in Sweden: a nationwide cohort study. *Ann. Intern. Med.* <https://doi.org/10.7326/m20-6367> (2021).
- Riley, T., Nethery, E., Chung, E. K. & Souter, V. Impact of the COVID-19 pandemic on perinatal care and outcomes in the United States: an interrupted time series analysis. *Birth* <https://doi.org/10.1111/birt.12606> (2021).
- Sun, S., Savitz, D. A. & Wellenius, G. A. Changes in adverse pregnancy outcomes associated with the COVID-19 pandemic in the United States. *JAMA Netw. Open* **4**, e2129560 (2021).
- Liu, S. et al. Pregnancy outcomes during the COVID-19 pandemic in Canada, March to August 2020. *J. Obstet. Gynaecol. Can.* **43**, 1406–1415 (2021).
- Khalil, A. et al. Change in the incidence of stillbirth and preterm delivery during the COVID-19 pandemic. *JAMA* <https://doi.org/10.1001/jama.2020.12746> (2020).
- Okeke, E. N., Abubakar, I. S. & De Guttery, R. In Nigeria, stillbirths and newborn deaths increased during the COVID-19 pandemic. *Health Aff.* <https://doi.org/10.1377/hlthaff.2021.00659> (2021).
- Vaccaro, C., Mahmoud, F., Aboulatta, L., Aloud, B. & Eltonsy, S. The impact of COVID-19 first wave national lockdowns on perinatal outcomes: a rapid review and meta-analysis. *BMC Pregnancy Childbirth* **21**, 676 (2021).
- Yang, J. et al. COVID-19 pandemic and population-level pregnancy and neonatal outcomes: a living systematic review and meta-analysis. *Acta Obstet. Gynecol. Scand.* **100**, 1756–1770 (2021).
- Chmielewska, B. et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. *Lancet Glob. Health* **9**, e759–e772 (2021).
- Ochoa, L. B., Brockway, M., Stock, S. J. & Been, J. V. COVID-19 and maternal and perinatal outcomes. *Lancet Glob. Health* **9**, e1063–e1064 (2021).
- Chiesa, V., Antony, G., Wismar, M. & Rechel, B. COVID-19 pandemic: health impact of staying at home, social distancing and 'lockdown' measures—a systematic review of systematic reviews. *J. Public Health* **43**, e462–e481 (2021).
- Goldenberg, R. L., Culhane, J. F., Iams, J. D. & Romero, R. Epidemiology and causes of preterm birth. *Lancet* **371**, 75–84 (2008).
- Todd, I. M. F., Miller, J. E., Rowe, S. L., Burgner, D. P. & Sullivan, S. G. Changes in infection-related hospitalizations in children following pandemic restrictions: an interrupted time-series analysis of total population data. *Int. J. Epidemiol.* **50**, 1435–1443 (2021).
- Jones, N. How COVID-19 is changing the cold and flu season. *Nature* **588**, 388–390 (2020).

33. Stieb, D. M., Chen, L., Eshoul, M. & Judek, S. Ambient air pollution, birth weight and preterm birth: a systematic review and meta-analysis. *Environ. Res.* **117**, 100–111 (2012).
34. Ju, L. et al. Maternal air pollution exposure increases the risk of preterm birth: evidence from the meta-analysis of cohort studies. *Environ. Res.* **202**, 111654 (2021).
35. Venter, Z. S., Aunan, K., Chowdhury, S. & Lelieveld, J. COVID-19 lockdowns cause global air pollution declines. *Proc. Natl Acad. Sci. USA* **117**, 18984–18990 (2020).
36. Sarmadi, M., Rahimi, S., Rezaei, M., Sanaei, D. & Dianatinasab, M. Air quality index variation before and after the onset of COVID-19 pandemic: a comprehensive study on 87 capital, industrial and polluted cities of the world. *Environ. Sci. Eur.* **33**, 134 (2021).
37. Kotlar, B., Gerson, E., Petrillo, S., Langer, A. & Tiemeier, H. The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. *Reprod. Health* **18**, 10 (2021).
38. Hale, T., et al. Oxford COVID-19 Government Response Tracker. *Blavatnik School of Government* www.bsg.ox.ac.uk/covidtracker (2020).
39. Ashorn, P. et al. The Lancet Small Vulnerable Newborn Series: science for a healthy start. *Lancet* **396**, 743–745 (2020).
40. Kramer, M. S., Zhang, X. & Platt, R. W. Analyzing risks of adverse pregnancy outcomes. *Am. J. Epidemiol.* **179**, 361–367 (2014).
41. Ananth, C. V. & Vintzileos, A. M. Epidemiology of preterm birth and its clinical subtypes. *J. Matern. Fetal Neonatal Med.* **19**, 773–782 (2006).
42. Cuestas, E. et al. Association between COVID-19 mandatory lockdown and decreased incidence of preterm births and neonatal mortality. *J. Perinatol.* **41**, 2566–2569 (2021).
43. Khalil, A. et al. Change in obstetric attendance and activities during the COVID-19 pandemic. *Lancet Infect. Dis.* [https://doi.org/10.1016/s1473-3099\(20\)30779-9](https://doi.org/10.1016/s1473-3099(20)30779-9) (2020).
44. Allotey, J. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *Brit. Med. J.* **370**, m3320 (2020).
45. Villar, J. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr.* **175**, 817–826 (2021).
46. Stock, S. J. et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. *Nat. Med.* <https://doi.org/10.1038/s41591-021-01666-2> (2022).
47. Walani, S. R. Global burden of preterm birth. *Int. J. Gynaecol. Obstet.* **150**, 31–33 (2020).
48. von Wissmann, B. et al. Informing prevention of stillbirth and preterm birth in Malawi: development of a minimum dataset for health facilities participating in the DIPLOMATIC collaboration. *BMJ Open* **10**, e038859 (2020).
49. World Health Organization & Others. Every newborn: an action plan to end preventable deaths. *WHO, UNICEF* https://apps.who.int/iris/bitstream/handle/10665/127938/9789241507448_eng.pdf (2014).
50. Brabin, P. et al. The International Stillbirth Alliance: connecting for life. *Lancet* **377**, 1313 (2011).
51. Frøen, J. F. et al. Stillbirths: progress and unfinished business. *Lancet* **387**, 574–586 (2016).
52. Homer, C. S. E. et al. Counting stillbirths and COVID 19-there has never been a more urgent time. *Lancet Glob. Health* **9**, e10–e11 (2021).
53. Lee, S. J., Steer, P. J. & Filippi, V. Seasonal patterns and preterm birth: a systematic review of the literature and an analysis in a London-based cohort. *BJOG* **113**, 1280–1288 (2006).
54. Frøen, J. F. et al. eRegistries: Electronic registries for maternal and child health. *BMC Pregnancy Childbirth* **16**, 11 (2016).
55. Stock, S. J. et al. The international Perinatal Outcomes in the Pandemic (iPOP) study: protocol. *Wellcome Open Res.* **6**, 21 (2021).
56. von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull. World Health Organ.* **85**, 867–872 (2007).
57. Jones, K. H., Ford, D. V., Thompson, S. & Lyons, R. A. A Profile of the SAIL Databank on the UK Secure Research Platform. *Int. J. Popul. Data Sci.* **4**, 1134 (2019).
58. The World Bank - DataBank *The World Bank* <https://databank.worldbank.org/home.aspx> (2022).
59. Lawn, J. E. et al. Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. *BMC Pregnancy Childbirth* **10 Suppl 1**, S1 (2010).
60. World Health Organization *Neonatal and perinatal mortality: country, regional and global estimates* (World Health Organization, 2006).
61. Quinn, J.-A. et al. Preterm birth: case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. *Vaccine* **34**, 6047–6056 (2016).
62. Bernal, J. L., Cummins, S. & Gasparrini, A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int. J. Epidemiol.* **46**, 348–355 (2017).
63. Akaike, H. in *Selected Papers of Hirotugu Akaike* (eds Parzen, E. et al.) 199–213 (Springer, 1998).
64. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control. Clin. Trials* **7**, 177–188 (1986).
65. Konstantopoulos, S. Fixed effects and variance components estimation in three-level meta-analysis. *Res. Synth. Methods* **2**, 61–76 (2011).
66. Higgins, J. P. T., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. *Brit. Med. J.* **327**, 557–560 (2003).

Acknowledgements

Funding and in-kind support: This work was supported by the International COVID-19 Data Alliance (ICODA), an initiative funded by the Bill and Melinda Gates Foundation and Minderoo as part of the COVID-19 Therapeutics Accelerator and convened by Health Data Research (HDR) UK, in addition to support from the HDR UK BREATHE Hub. Several ICODEA partners contributed to the study, including: Cytel (statistical support), the Odd Group (data visualization) and Aridhia Informatics (development of federated analysis using a standardized protocol ([Common API] <https://github.com/federated-data-sharing/>) to be used in future work). Additional contributors: We acknowledge the important contributions from the following individuals: A. C. Hennemann and D. Suguitani (patient partners from Prematuridade: Brazilian Parents of Premies' Association, Porto Alegre, Brazil); N. Postlethwaite (implementation of processes supporting the trustworthy collection, governance and analysis of data from ICODEA, HDR UK, London, UK); A. S. Babatunde (led data acquisition from University of Uyo Teaching Hospital, Uyo, Nigeria); N. Silva (data quality, revision and visualization assessment from Methods, Analytics and Technology for Health (M.A.T.H) Consortium, Belo Horizonte, Brazil); J. Söderling (data management from the Karolinska Institutet, Stockholm, Sweden). We also acknowledge the following individuals who assisted with data collection efforts: R. Goemaes (Study Centre for Perinatal Epidemiology (SPE), Brussels, Belgium); C. Leroy (Le Centre d'Épidémiologie Périnatale (CEPiP), Brussels, Belgium); J. Gamba and K. Ronald (St. Francis Nsambya Hospital, Kampala, Uganda); M. Heidarzadeh (Tabriz Medical University, Tabriz, Iran); M. J. Ojeda (Pontificia Universidad Católica de Chile, Santiago, Chile); S. Nangia (Lady Hardinge Medical College, New Delhi, India);

C. Nelson, S. Metcalfe and W. Luo (Maternal Infant Health Section of the Public Health Agency of Canada, Ottawa, Canada); K. Sitcov (Foundation for Health Care Quality, Seattle, United States); A. Valek (Semmelweis University, Budapest, Hungary); M. R. Yanlin Liu (Mater Data and Analytics, Brisbane, Australia). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions

C.C. prepared, analysed and interpreted data, and led writing of the manuscript. J.E.M. contributed to planning and conducting the study, analysed and interpreted data, and contributed to drafting the manuscript. M.B.A., M.B., D.B., N.R., S.J.S. and H.Z. were iPOP study co-leads, contributed to planning and conducting the study, interpreted data and contributed to drafting the manuscript. J.V.B., J.R.B., R.B., K.N.C.T., I.O.F.D., S.E.O., M.G., S.E.H., L. Huicho., S.K., R.K., J.L., L.A.M., M.C.M., N.N., A.O., O.A.O., R.O.O., L.H.P., H.G.Q.-P., A.K.R., T.A.R., T.A.H.R., C.S., M.S., L.T., R.W., C.S.Y. and A.Z. contributed to planning and conducting the study, interpreted data and contributed to drafting the manuscript. C.D.A., A.K.A., A.I.A., F.B., L.C., C.D., S.C., M.D., K.E., H.E., O.W.G., L.A.G., K.K.C.M., P.M.M., R.P.M., L.N.B., L.O., A.K.O., J.O., O.O., G.P., I.P., A.R.-P., N.R.R., D.L.R., F.J.S., O.S. and I.C.K.W. acquired data and/or interpreted data, and contributed to drafting the manuscript. N.A., M.C.-Y., D.-T.C., K.L.C., M.F., A.H., L. Hui, J.H., A.K., R.H.M., S.D.N., K.R.P., R.K.P., E.M.S., M.T., M.L.U., P.vD., C.W. and K.Y.-A. contributed to planning and conducting studies and revising the manuscript. I.I.A., B.B., K.B., G.E.-G., J.H., L. Hookham, S.H., N.K., J.K., K.L.D., N.M., V.N., C.O., D.P., M.P., C.S. and K.W.-S. acquired and/or interpreted and/or analysed data. A.B., L.R.B., I.F., A.F., T.O.O., S.S. and G.A.W. contributed to drafting the manuscript. Z.A.B., A.D.M. and A.S. contributed to planning and conducting studies, critical appraisal and contribution to this work as well as contributed to securing funds. All other authors reviewed and provided input to the manuscript.

Competing interests

M.B.A. holds a Tier 2 Canada Research Chair in the Developmental Origins of Chronic Disease at the University of Manitoba and is a Fellow in the Canadian Institutes for Advanced Research (CIFAR) Humans and the Microbiome Program. Her effort on this project was partly supported by HDR UK and ICODA. K.K.C.M. declares support from The Innovation and Technology Commission of the Hong Kong Special Administrative Region Government, and Hong Kong Research Grants Council Collaborative Research Fund Coronavirus Disease (COVID-19) and Novel Infectious Disease Research Exercise (Ref: C7154-20G) and grants from C W Maplethorpe Fellowship, National Institute of Health Research UK, European Commission Framework Horizon 2020 and has consulted for IQVIA Ltd. A.S. is supported by ICODA and HDR UK, and has received a research grant from HDR UK to the BREATHE Hub. He participates on the Scottish and UK Government COVID-19 Advisory Committees, unremunerated. S.J.S. is supported by a Wellcome Trust Clinical Career Development Fellowship (209560/Z/17/Z) and HDR UK, and has received personal fees from Hologic and Naterra outside the submitted work. D.B. is supported by a National Health and Medical Research Council (Australia) Investigator Grant (GTN1175744). I.C.K.W. declares support from The Innovation and Technology Commission of the Hong Kong Special Administrative Region Government, and Hong Kong Research Grants Council Collaborative Research Fund Coronavirus Disease (COVID-19) and Novel Infectious Disease Research Exercise (Ref: C7154-20G), and grants from Hong Kong Research Grant Council, National Institute of Health Research UK, and European Commission Framework Horizon 2020. H.Z. is supported by a UNSW Scientia Program Award and reports grants from European Commission Framework Horizon 2020, Icelandic Centre for Research, and Australia's National Health and Medical

Research Council. H.Z. was an employee of the UNSW Centre for Big Data Research in Health, which received funding from AbbVie Australia to conduct research, unrelated to the current study. I.I.A.A., C.D.A., K.A., A.I.A., L.C., S.S., G.E.-G., O.W.G., L. Huicho, S.H., A.K., K.L., V.N., I.P., N.R.R., T.R., T.A.H.R., V.L.S., E.M.S., L.T., R.W. and H.Z. received funding from HDRUK (grant #2020.106) to support data collection for the iPOP study. K.H., R.B., S.O.E., A.R.-P. and J.H. receive salary from ICODA. M.B. received trainee funding from HDRUK (grant #2020.106). J.E.M. received trainee funding from HDRUK (grant #2020.109). Other relevant funding awarded to authors to conduct research for iPOP include: M.G. received funding from THL, Finnish Institute for Health and Welfare to support data collection. K.D. received funding from EDCTP RIA2019 and HDRUK (grant #2020.106) to support data collection. R.B. received funding from Alzheimer's Disease Data Initiative and ICODA for the development of federated analysis. A.D.M. received funding from HDR UK who receives its funding from the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and the Wellcome Trust; and Administrative Data Research UK, which is funded by the Economic and Social Research Council (grant ES/SO07393/1). N.A. received funding from the National Institutes of Health (R35GM138353). O.S. received funding from NordForsk (grant #105545). The remaining authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s41562-023-01522-y>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41562-023-01522-y>.

Correspondence and requests for materials should be addressed to David Burgner, Sarah J. Stock or Meghan B. Azad.

Peer review information *Nature Human Behaviour* thanks Aliko Christou and Jane Hirst for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Clara Calvert ^{1,115}, Meredith (Merilee) Brockway^{2,115}, Helga Zoega ^{3,4,115}, Jessica E. Miller ^{5,6,115}, Jasper V. Been ⁷, Adeladza Kofi Amegah ⁸, Amy Racine-Poon⁹, Solmaz Eradat Oskoui¹, Ishaya I. Abok ¹⁰, Nima Aghaeepour ¹¹, Christie D. Akwaowo ^{12,13}, Belal N. Alshaikh ¹⁴, Adejumo I. Ayede ¹⁵, Fabiana Bacchini ¹⁶, Behzad Barekatin ¹⁷, Rodrigo Barnes ¹⁸, Karolina Bebak¹⁹, Anick Berard^{20,21,22}, Zulfiqar A. Bhutta^{23,24}, Jeffrey R. Brook²⁵, Lenroy R. Bryan ²⁶, Kim N. Cajachagua-Torres ^{27,28,29}, Marsha Campbell-Yeo³⁰, Dinh-Toi Chu³¹, Kristin L. Connor ³², Luc Cornette³³, Sandra Cortés ³⁴, Mandy Daly³⁵, Christian Debauche^{36,37}, Iyabode Olabisi F. Dedek³⁸, Kristjana Einarsdóttir ^{4,39}, Hilde Engjom ⁴⁰, Guadalupe Estrada-Gutierrez ⁴¹, Ilaria Fantasia ⁴², Nicole M. Fiorentino², Meredith Franklin ⁴³, Abigail Fraser⁴⁴, Onesmus W. Gachuno⁴⁵, Linda A. Gallo⁴⁶, Mika Gissler^{47,48,49}, Siri E. Håberg⁵⁰, Abbas Habibelahi⁵¹, Jonas Häggström⁵², Lauren Hookham ⁵³, Lisa Hui⁵⁴, Luis Huicho ⁵⁵, Karen J. Hunter ¹, Sayeeda Huq⁵⁶, Ashish KC ⁵⁷, Seilesh Kadambari⁵⁸, Roya Kelishadi⁵⁹, Narjes Khalili⁶⁰, Joanna Kippen¹⁹, Kirsty Le Doare^{61,62}, Javier Llorca^{63,64}, Laura A. Magee ⁶⁵, Maria C. Magnus⁵⁰, Kenneth K. C. Man ^{66,67,68}, Patrick M. Mburugu ⁶⁹, Rishi P. Mediratta ⁷⁰, Andrew D. Morris⁷¹, Nazeem Muhajarine⁷², Rachel H. Mulholland¹, Livia Nagy Bonnard⁷³, Victoria Nakibuuka⁷⁴, Natasha Nassar⁷⁵, Sylvester D. Nyadanu ^{39,76}, Laura Oakley ^{50,77}, Adesina Oladokun ⁷⁸, Oladapo O. Olayemi⁷⁸, Olanike A. Olutekunbi ⁷⁹, Rosena O. Oluwafemi ⁸⁰, Taofik O. Ogunkunle ⁸¹, Chris Orton⁸², Anne K. Örtqvist^{83,84}, Joseph Ouma ⁸⁵, Oyejoke Oyapero⁸⁶, Kirsten R. Palmer ⁸⁷, Lars H. Pedersen ⁸⁸, Gavin Pereira ^{50,89}, Isabel Pereyra ⁹⁰, Roy K. Philip ⁹¹, Dominik Pruski¹⁹, Marcin Przybylski¹⁹, Hugo G. Quezada-Pinedo^{27,28,29}, Annette K. Regan⁹², Natasha R. Rhoda^{93,94}, Tonia A. Rihs⁹⁵, Taylor Riley⁹⁶, Thiago Augusto Hernandez Rocha⁹⁷, Daniel L. Rolnik ⁸⁷, Christoph Saner ^{5,98,99}, Francisco J. Schneuer ¹⁰⁰, Vivienne L. Souter¹⁰¹, Olof Stephansson ⁸³, Shengzhi Sun¹⁰², Emma M. Swift¹⁰³, Miklós Szabó¹⁰⁴, Marleen Temmerman ¹⁰⁵, Lloyd Tooke ¹⁰⁶, Marcelo L. Urquia¹⁰⁷, Peter von Dadelszen ⁶⁵, Gregory A. Wellenius ¹⁰², Clare Whitehead¹⁰⁸, Ian C. K. Wong ^{66,67,68}, Rachael Wood ^{1,109}, Katarzyna Wróblewska-Seniuk ¹¹⁰, Kojo Yeboah-Antwi ¹¹¹, Christopher S. Yilgwan¹¹², Agnieszka Zawiejska ¹¹³, Aziz Sheikh ¹, Natalie Rodriguez², David Burgner ^{5,6,116} , Sarah J. Stock ^{1,116} , & Meghan B. Azad ^{2,114,116} 

¹Usher Institute, University of Edinburgh, Edinburgh, UK. ²Children's Hospital Research Institute of Manitoba, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada. ³School of Population Health, Faculty of Medicine & Health, University of New South Wales Sydney, Sydney, New South Wales, Australia. ⁴Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ⁵Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia. ⁶Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia. ⁷Division of Neonatology, Department of Paediatrics; Department of Obstetrics and Gynaecology; Department of Public Health; Erasmus MC - Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, the Netherlands. ⁸Public Health Research Group, Department of Biomedical Sciences, University of Cape Coast, Cape Coast, Ghana. ⁹Novartis, Basel, Switzerland. ¹⁰Department of Pediatrics, University of Jos/Jos University Teaching Hospital, Jos, Nigeria. ¹¹Department of Anesthesiology, Pain, and Perioperative Medicine, Stanford University School of Medicine, Stanford, CA, USA. ¹²Institute of Health Research and Development, University of Uyo Teaching Hospital, Uyo, Nigeria. ¹³College of Health Sciences, University of Uyo, Uyo, Nigeria. ¹⁴Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada. ¹⁵Department of Pediatrics, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria. ¹⁶Canadian Premature Babies Foundation, Toronto, Ontario, Canada. ¹⁷Department of Pediatrics, Division of Neonatology, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. ¹⁸Aridhia Informatics, Glasgow, UK. ¹⁹Obstetrics and Gynaecology Ward, District Public Hospital in Poznań, Poznań, Poland. ²⁰Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. ²¹CHU Ste-Justine, Montreal, Quebec, Canada. ²²Faculty of Medicine, Université Claude Bernard Lyon 1, Lyon, France. ²³Center of Excellence in Women Child Health, The Aga Khan University, Karachi, Pakistan. ²⁴Centre for Global Child Health, Hospital for Sick Children, Toronto, Ontario, Canada. ²⁵Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. ²⁶Department of Obstetrics & Gynaecology and Child Health, University of The West Indies, Mona, Jamaica. ²⁷The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ²⁸The Department of Paediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. ²⁹Centro de Investigación en Salud Materna e Infantil and Centro de Investigación para el Desarrollo Integral y Sostenible, Universidad Peruana Cayetano Heredia, Lima, Peru. ³⁰School of Nursing, Dalhousie University and IWK Health, Halifax, Nova Scotia, Canada. ³¹Center for Biomedicine and Community Health, International School, Vietnam National University, Hanoi, Vietnam. ³²Department of Health Sciences, Carleton University, Ottawa, Ontario, Canada. ³³AZ St-Jan Bruges-Ostend AV Hospital, Bruges, Belgium. ³⁴Department of Public Health, School of Medicine, Advanced Center for Chronic Diseases Diagonal (ACCDIS), Santiago, Chile. ³⁵Irish Neonatal Health Alliance, Wicklow, Ireland. ³⁶Department of Neonatology, Cliniques Universitaires Saint-Luc, IREC, UCLouvain, Brussels, Belgium. ³⁷CEpiP (Centre d'Epidémiologie Périnatale), Brussels, Belgium. ³⁸Department of Paediatrics, Federal Medical Centre, Abeokuta, Nigeria. ³⁹Curtin School of Population Health, Curtin University, Perth, Western Australia, Australia. ⁴⁰Department of Health Registry Research and Development, Norwegian Institute of Public Health, Oslo, Norway. ⁴¹National Institute of Perinatology, Mexico City, Mexico. ⁴²Institute for Maternal and Child Health, IRCCS Burlo Garofolo Children's Hospital, Trieste, Italy. ⁴³Department of Statistical Sciences and School of the Environment, University of Toronto, Toronto, Ontario, Canada. ⁴⁴Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. ⁴⁵Obstetrics and Gynecology, Medicine, University of Nairobi, Nairobi, Kenya. ⁴⁶School of Biomedical Sciences, The University of Queensland, St. Lucia, Queensland, Australia. ⁴⁷Department of Knowledge Brokers, THL Finnish Institute for Health and Welfare, Helsinki, Finland. ⁴⁸Academic Primary Health Care Centre, Region Stockholm, Stockholm, Sweden. ⁴⁹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ⁵⁰Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. ⁵¹Neonatology, Neonatal Health Office, Ministry of Health and Medical Education, Tehran, Iran. ⁵²Cytel, Waltham, MA, USA. ⁵³St. George's University, Makerere University - Johns Hopkins University Research Collaboration, London, UK. ⁵⁴Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia. ⁵⁵Centro de Investigación en Salud Materna e Infantil, Centro de Investigación para el Desarrollo Integral y Sostenible and School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru. ⁵⁶Nutrition and Clinical Services Division, ICDDR,B (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh. ⁵⁷Uppsala University, Uppsala, Sweden. ⁵⁸Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.


⁵⁹Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran. ⁶⁰Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Department of Community and Family Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. ⁶¹International Centre for Neonatal and Paediatric Infection, St. George's, University of London, London, UK. ⁶²Medical Research Council/Uganda Virus Research Institute and London School of Medical Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda. ⁶³Universidad de Cantabria, Santander, Spain. ⁶⁴CIBERESP (Consortium for Biomedical Research in Epidemiology & Public Health, en Epidemiología y Salud Pública), Madrid, Spain. ⁶⁵Institute of Women and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK. ⁶⁶Research Department of Practice and Policy, University College London School of Pharmacy, London, UK. ⁶⁷Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong. ⁶⁸Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong, Hong Kong. ⁶⁹Department of Child Health and Paediatrics, School of Medicine, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. ⁷⁰Division of Pediatric Hospital Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. ⁷¹Health Data Research UK, London, UK. ⁷²Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. ⁷³Melletted a helyem Egység, Right(s) Beside You Association, Budapest, Hungary. ⁷⁴Department of Paediatrics, St. Francis Nsambya Hospital, Kampala, Uganda. ⁷⁵Child Population and Translational Health Research, Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. ⁷⁶Education, Culture, and Health Opportunities (ECHO) Research Group International, Aflao, Ghana. ⁷⁷Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. ⁷⁸Department of Obstetrics and Gynaecology, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria. ⁷⁹Lagos Island Maternity Hospital, Lagos, Nigeria. ⁸⁰Department of Paediatrics and Child Health, Mother and Child Hospital, Akure, Nigeria. ⁸¹Department of Paediatrics, Dalhatu Araf Specialist Hospital, Lafia, Nigeria. ⁸²Swansea University, Swansea, UK. ⁸³Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden. ⁸⁴Department of Obstetrics and Gynecology, Visby County Hospital, Visby, Sweden. ⁸⁵Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda. ⁸⁶Paediatrics Department, Ikorodu General Hospital, Ikorodu, Nigeria. ⁸⁷Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. ⁸⁸Department of Obstetrics and Gynecology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark. ⁸⁹Curtin School of Population Health and enAble Institute, Curtin University, Perth, Western Australia, Australia. ⁹⁰School of Nutrition, Catholic University del Maule, Region del Maule, Chile. ⁹¹Division of Neonatology, Department of Paediatrics, University Maternity Hospital Limerick and University of Limerick School of Medicine, Limerick, Ireland. ⁹²School of Nursing and Health Professions, University of San Francisco, San Francisco, CA, USA. ⁹³Paediatric Department, School of Adolescent and Child Health, University of Cape Town, Cape Town, South Africa. ⁹⁴Mowbray Maternity Hospital, Western Cape Department of Health, Cape Town, South Africa. ⁹⁵Federal Statistical Office (FSO), Neuchâtel, Switzerland. ⁹⁶Department of Epidemiology, University of Washington, Seattle, WA, USA. ⁹⁷Evidence and Intelligence for Action in Health Department, Pan-American Health Organization - World Health Organization, Washington, DC, USA. ⁹⁸Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ⁹⁹Department of Biomedical Research, University of Bern, Bern, Switzerland. ¹⁰⁰The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. ¹⁰¹Foundation for Health Care Quality, Seattle, WA, USA. ¹⁰²Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA. ¹⁰³Faculty of Nursing, Department of Midwifery, University of Iceland, Reykjavik, Iceland. ¹⁰⁴Division of Neonatology, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary. ¹⁰⁵Centre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya. ¹⁰⁶Department of Paediatrics, University of Cape Town, Cape Town, South Africa. ¹⁰⁷Manitoba Centre for Health Policy, Department of Community Health Sciences, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. ¹⁰⁸The Royal Women's Hospital, University of Melbourne, Melbourne, Victoria, Australia. ¹⁰⁹Public Health Scotland, Edinburgh, UK. ¹¹⁰II Department of Neonatology, Poznań University of Medical Sciences, Poznań, Poland. ¹¹¹Public Health Unit, Father Thomas Alan Rooney Memorial Hospital, Asankrangwa, Western Region, Ghana. ¹¹²Department of Paediatrics, University of Jos, Jos, Nigeria. ¹¹³Department of Medical Simulation, Chair of Medical Education, Poznań University of Medical Sciences, Poznań, Poland. ¹¹⁴Departments of Pediatrics and Child Health, Community Health Sciences, and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada, Winnipeg, Manitoba, Canada. ¹¹⁵These authors contributed equally: Clara Calvert, Meredith Brockway, Helga Zoega, Jessica E. Miller. ¹¹⁶These authors jointly supervised this work: David Burgner, Sarah J. Stock, Meghan B. Azad. ✉ e-mail: david.burgner@mcri.edu.au; sarah.stock@ed.ac.uk; meghan.azad@umanitoba.ca



Extended Data Fig. 1 | Observed rates of very preterm births (amongst all births 22 weeks onwards) over time (2015–2020) for countries with population-based data, with the forecasted very preterm births and 95% confidence intervals also plotted for the lockdown period. Lockdown period shown in shaded grey. Unless specified otherwise, very preterm birth rates are the percentage of all births from 22 weeks onwards that were born before 32 weeks gestation. Left panel: entire study period (2015–2020) illustrating

seasonality and trends over time. Right panel: 2020 period enlarged to show the observed and forecasted very preterm birth rates during lockdown. Forecasted ('modelled') rates were estimated from a 'pre-lockdown model' which was used to forecast the expected rates of very preterm birth for each of the first four months of lockdown assuming lockdown had not occurred. *Very preterm birth rates restricted to births from 24 weeks onwards; **Very preterm birth rates restricted to live births only.


Spontaneous preterm birth rate (%)



Extended Data Fig. 2 | Observed rates of spontaneous preterm births (amongst all births 22 weeks onwards) over time (2015–2020) for countries with population-based data, with the forecasted spontaneous preterm births and 95% confidence intervals also plotted for the lockdown period. Lockdown period shown in shaded grey. Unless specified otherwise, spontaneous preterm birth rates are the percentage of all births from 22 weeks onwards that were born before 37 weeks gestation and where the birth was preceded by spontaneous contractions or preterm prelabour rupture of

membranes. Left panel: entire study period (2015–2020) illustrating seasonality and trends over time. Right panel: 2020 period enlarged to show the observed and forecasted spontaneous preterm birth rates during lockdown. Forecasted ('modelled') rates were estimated from a 'pre-lockdown model' which was used to forecast the expected rates of spontaneous preterm birth for each of the first four months of lockdown assuming lockdown had not occurred. *Spontaneous preterm birth rates restricted to births from 24 weeks onwards; **Spontaneous preterm birth rates restricted to live births only.

Stillbirth rate (per 1000 births)





Extended Data Fig. 3 | Observed rates of stillbirth (amongst all births 22 weeks onwards) over time (2015-2020) for countries with population-based data, with the forecasted stillbirth rates and 95% confidence intervals also plotted for the lockdown period. Lockdown period shown in shaded grey. Unless specified otherwise, stillbirth rates are the number of all births from 22 weeks onwards that were stillborn expressed per 1000 births. Left panel: entire

study period (2015-2020) illustrating seasonality and trends over time. Right panel: 2020 period enlarged to show the observed and forecasted stillbirth rates during lockdown. Forecasted ('modelled') rates were estimated from a 'pre-lockdown model' which was used to forecast the expected rates of stillbirth for each of the first four months of lockdown assuming lockdown had not occurred. *Stillbirths rates restricted to births from 24 weeks onwards.

Preterm Birth


1st month of lockdown



Extended Data Fig. 4 | Individual and pooled non-population-based estimates of the association between lockdown and the odds of preterm birth among all births 22 weeks onwards, stratified by time since lockdown. Individual odds ratios (represented by boxes on plot) for each dataset were calculated by comparing the observed odds of preterm birth to the forecasted odds of preterm birth from a linear regression model that was fitted to pre-

lockdown data. Horizontal lines surrounding each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of preterm birth were calculated using random-effects meta-analysis. Sample sizes for each dataset provided in Table 2.*Births from 24 weeks onwards; **Live births only.

Very Preterm Birth





Extended Data Fig. 5 | Individual and pooled population-based estimates of the association between lockdown and the odds of very preterm birth among all births 22 weeks onwards, stratified by time since lockdown. Individual country odds ratios (represented by boxes on plot) were calculated by comparing the observed odds of very preterm birth to the forecasted odds of very preterm birth from an interrupted time series model that was fitted to

pre-lockdown data. Horizontal lines surrounding each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of very preterm birth were calculated using random-effects meta-analysis. Sample sizes for each country provided in Table 1. *Births from 24 weeks onwards; **Live births only.

Very Preterm Birth


1st month of lockdown



Extended Data Fig. 6 | Individual and pooled non-population-based estimates of the association between lockdown and the odds of very preterm birth among all births 22 weeks onwards, stratified by time since lockdown. Individual odds ratios (represented by boxes on plot) for each dataset were calculated by comparing the observed odds of very preterm birth to the forecasted odds of very preterm birth from a linear regression model that was

fitted to pre-lockdown data. Horizontal lines surrounding each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of very preterm birth were calculated using random-effects meta-analysis. Sample sizes for each dataset provided in Table 2.

Spontaneous Preterm Birth





Extended Data Fig. 7 | Individual and pooled population-based estimates of the association between lockdown and the odds of spontaneous preterm birth among all births 22 weeks onwards, stratified by time since lockdown. Individual country odds ratios (represented by boxes on plot) were calculated by comparing the observed odds of spontaneous preterm birth to the forecasted odds of spontaneous preterm birth from an interrupted time series model that

was fitted to pre-lockdown data. Horizontal lines surrounding each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of spontaneous preterm birth were calculated using random-effects meta-analysis. Sample sizes for each country provided in Table 1. *Births from 24 weeks onwards; **Live births only.

Spontaneous Preterm Birth

1st month of lockdown





Extended Data Fig. 8 | Individual and pooled non-population-based estimates of the association between lockdown and the odds of spontaneous preterm birth among all births 22 weeks onwards, stratified by time since lockdown. Individual odds ratios (represented by boxes on plot) for each dataset were calculated by comparing the observed odds of spontaneous preterm birth to the forecasted odds of spontaneous preterm birth from a linear regression

model that was fitted to pre-lockdown data. Horizontal lines surrounding each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of spontaneous preterm birth were calculated using random-effects meta-analysis. Sample sizes for each dataset provided in Table 2.

Stillbirth

1st month of lockdown





Extended Data Fig. 9 | Individual and pooled population-based estimates of the association between lockdown and the odds of stillbirth among all births 22 weeks onwards, stratified by time since lockdown. Individual country odds ratios (represented by boxes on plot) were calculated by comparing the observed odds of stillbirth to the forecasted odds of stillbirth from an interrupted time series model that was fitted to pre-lockdown data. Horizontal lines surrounding

each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of preterm birth were calculated using random-effects meta-analysis. Sample sizes for each country provided in Table 1. *Per 1000 births; **Births from 24 weeks onwards.

Stillbirth

1st month of lockdown



Extended Data Fig. 10 | Individual and pooled non-population-based estimates of the association between lockdown and the odds of stillbirth all births 22 weeks onwards, stratified by time since lockdown. Individual odds ratios (represented by boxes on plot) for each dataset were calculated by comparing the observed odds of stillbirth to the forecasted odds of stillbirth from a linear regression model that was fitted to pre-lockdown data. Horizontal

lines surrounding each box on the forest plot are 95% confidence intervals. Pooled odds ratios (represented by diamonds on plot) for the association between lockdown and the odds of stillbirth were calculated using random-effects meta-analysis. Sample sizes for each dataset provided in Table 2. *Per 1000 births; **Restricted to births from 28 weeks onwards.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a | Confirmed |
|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of all covariates tested |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

This study makes use of anonymized data held in the Secure Anonymized Information Linkage (SAIL) Databank. We would like to acknowledge all the data providers who made anonymized data available for research (listed in Supplementary Table 1). The responsibility for the interpretation of the information SAIL supplied is the authors' alone. Data may be available to researchers for analysis after securing relevant permissions from the data contributors and the databank in which the data are held (SAIL Databank). The approvals process is managed by application to the SAIL Databank who hold data sharing agreements with the data providers.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	We do not look at sex/gender in this paper.
Population characteristics	This study was a secondary analysis utilizing aggregate data on the monthly number of births broken down by gestational age at birth groups. There was further disaggregation available in some datasets by whether they were live births or stillbirths and, specifically for preterm births (i.e., births at <37 weeks gestation), by whether they were spontaneous preterm births. There were no individual level data available in these datasets.
Recruitment	This was a secondary data analysis so there was no recruitment undertaken as part of the study.
Ethics oversight	Contributors from countries where the data were not publicly available obtained ethics approval from their respective institutional review boards (Supplementary Table 6). We did not seek ethical approval for publicly available data sources (Supplementary Table 6). All data contributors completed a Data Completion Agreement, which outlined the terms and conditions for uploading and storing data to the SAIL databank.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We ultimately included all eligible datasets in this analysis, with the sample size determined by this. For preterm birth, we are able to detect small changes with our sample size, particularly when we pool across all the datasets, so we are confident we have a sufficient sample size for this outcome. For stillbirth, which is a rarer outcome, there is greater uncertainty in our estimates (acknowledged in the discussion), but we still have sufficient power to detect associations for some countries.
Data exclusions	We excluded datasets if: (1) there were a small number of monthly births (<50) or (2) there was an insufficient timespan of data to reliably predict the expected preterm birth rates in the lockdown period or (2) there were implausible preterm birth rates in the dataset.
Replication	We undertook a number of sensitivity analyses varying our study population (for example, restricting to only live births), and examined the impact of removing large countries from the meta-analysis, none of which changed our conclusions.
Randomization	It would not be possible to randomize pregnant women to be exposed to pandemic-related restrictions ("lockdown") or not, so we instead relied on available aggregate level data to conduct this observational analysis. As with most analyses of aggregate level data, we were also unable to control for individual-level confounders that may affect the association between lockdown and our perinatal outcomes, as outlined in the limitations section in the Discussion.
Blinding	This study relied on aggregate level data extract from health facility records, electronic routine health records or national reporting systems. As all eligible births were included in the dataset and analysis, no blinding was required.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging